BD113vLVP / BDgene - LARVOL DELTA

CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation (clinicaltrials.gov) - P=N/A | N=9 | Suspended | Sponsor: Shanghai BDgene Co., Ltd. | Trial completion date: Dec 2025 ➔ Jul 2027 | Recruiting ➔ Suspended | Trial primary completion date: Dec 2025 ➔ Apr 2027

Trial completion date • Trial primary completion date • Trial suspension • Glaucoma • Ophthalmology

CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation (clinicaltrials.gov) - P=N/A | N=9 | Recruiting | Sponsor: Shanghai BDgene Co., Ltd.

New trial • Glaucoma • Ophthalmology